CCL2 and type 2 diabetes mellitus: Recent research indicates that omentin-1 can downregulate the expression of miR-27a and then suppress MCP-1 expression by targeting the Nrf2/Keap1 pathway, thereby decreasing the levels of serum creatinine (Scr), blood urea nitrogen (BUN), and urinary microalbumin (UMA), ultimately improving kidney function in patients with T2DM by ameliorating podocyte dysfunction and glomerular pathological changes (Song et al., 2018).